Emirats Àrabs Units - anglès - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

100ml glass bottle -

Emirats Àrabs Units - anglès - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

100ml glass bottle -

Emirats Àrabs Units - anglès - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

100ml glass bottle -

Emirats Àrabs Units - anglès - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

100 ml glass bottle -

Emirats Àrabs Units - anglès - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

doha drug & medical equipment store llc united states of america - 100’s glass bottle - capsule - 1000 mg - n/a

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - iotroxate meglumine, quantity: 105.46 mg/ml - injection, solution - excipient ingredients: sodium calcium edetate; sodium bicarbonate; sodium chloride; water for injections - biliscopin for infusion is indicated for radiological examination of hepatic and biliary ducts and gallbladder when examination by oral technique is unsuccessful or inappropriate.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - amisulpride 100mg;  ;  ; amisulpride 100mg - tablet - 100 mg - active: amisulpride 100mg     excipient: hydrated silica lactose monohydrate magnesium stearate methylcellulose potato starch active: amisulpride 100mg excipient: hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose sodium starch glycolate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - sodium valproate 100mg - tablet - 100 mg - active: sodium valproate 100mg excipient: hydrated silica light kaolin magnesium stearate maize starch purified water - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - levetiracetam, quantity: 100 mg/ml - solution - excipient ingredients: propyl hydroxybenzoate; purified water; ammonium glycyrrhizinate; acesulfame potassium; methyl hydroxybenzoate; sodium citrate dihydrate; glycerol; citric acid monohydrate; maltitol; flavour - levetiracetam gh oral solution is indicated for:,? use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment,of partial onset seizures with or without secondary generalisation,,? monotherapy in the treatment of partial onset seizures, with or without secondary,generalisation, in patients from 16 years of age with newly diagnosed epilepsy.,? add-on therapy in the treatment of myoclonic seizures in adults and adolescents from 12,years of age with juvenile myoclonic epilepsy (jme),,? add-on therapy in the treatment of primary generalized tonic clonic (pgtc) seizures in adults and,children from 4 years of age with idiopathic generalized epilepsy (ige)

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - levetiracetam, quantity: 100 mg/ml - solution - excipient ingredients: propyl hydroxybenzoate; maltitol; purified water; sodium citrate dihydrate; glycerol; ammonium glycyrrhizinate; methyl hydroxybenzoate; acesulfame potassium; citric acid monohydrate; flavour - apo-levitiracetam oral solution is indicated for:,? use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment,of partial onset seizures with or without secondary generalisation,,? monotherapy in the treatment of partial onset seizures, with or without secondary,generalisation, in patients from 16 years of age with newly diagnosed epilepsy.,? add-on therapy in the treatment of myoclonic seizures in adults and adolescents from 12,years of age with juvenile myoclonic epilepsy (jme),,? add-on therapy in the treatment of primary generalized tonic clonic (pgtc) seizures in adults and,children from 4 years of age with idiopathic generalized epilepsy (ige).